Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas

Menopause

Volumn 11, Issue 2, 2004, Pages 214-222

  Reed, Susan D ^a,b,c   Cushing Haugen, Kara L ^c   Daling, Janet R ^c,d   Scholes, Delia ^d,e   Schwartz, Stephen M ^c,d  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Case control study; Leiomyoma; Postmenopausal combined hormone therapy

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BENIGN TUMOR; BODY MASS; CLIMACTERIUM; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; RISK ASSESSMENT; SIDE EFFECT; UTERUS MYOMA; AGE; AGE DISTRIBUTION; CASE CONTROL STUDY; HOT FLUSH; LEIOMYOMA; MEDICAL RECORD; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; UTERUS CANCER;

ADULT; AGE DISTRIBUTION; AGE FACTORS; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; LEIOMYOMA; MEDICAL RECORDS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RETROSPECTIVE STUDIES; RISK FACTORS; UTERINE NEOPLASMS; WASHINGTON;

EID: 2342647501     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000082297.18134.51     Document Type: Article

References (34)

1. Vollenhoven BJ, Lawrence AS, Healy DL. Uterine fibroids: a clinical review. Br J Obstet Gynaecol 1990;97:285-298.
2. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-438.
3. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995; 172:14-18.
4. Brandon DD, Erickson TE, Keenan EJ, et al. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab 1995;80:1876-1881.
5. Howe SR, Gottardis NM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995; 136:4996-5003.
6. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-553.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
8. Sener AB, Seckin NC, Ozmen S, Gokmen O, Dogu N, Ekici E. The effects of hormone replacement therapy on uterine fibroids in post-menopausal women. Fertil Steril 1996;65:354-357.
9. Schwartz LB, Simcha L, Mark M, Nachtigall LE, Horan C, Goldstein SR. Does the use of postmenopausal hormone replacement therapy influence the size of uterine leiomyomata? A preliminary report. Menopause 1996;3:38-43.
10. Fedele L, Bianchi S, Raffaelli R, Zanconato G. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol 2000;88:91-94.
11. Romieu I, Walker AM, Jick S. Determinants of uterine leiomyoma. Post Market Surveil 1991;5:119-133.
12. Ramcharan S, Pelligrin FA, Ray R, et al. The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Center for Population Research Monograph. 1981; 3:69-74. NIH publication 81-564.
13. Beresford SA, Coker AL. Pictorially assisted recall of past hormone use in case-control studies. Am J Epidemiol 1989;130:202-205.
14. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982;116:114-122.
15. Hill DA, Weiss NS, Beresford SA, et al. Continuous-combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-1461.
16. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-2577.
17. Breslow NE, Day NE. Statistical Methods in Cancer Res, Volume II. Oxford, UK.: Oxford University Press, 1987:97.
18. Breslow NE, Day NE. Statistical Methods in Cancer Res, Volume I. Oxford, UK.: Oxford University Press, 1980:Section 6.7.
19. Ross RK, Pike MD, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine leiomyoma: reduced risk associates with oral contraceptives. Br Med J 1986;293:359-362.
20. Parazzini F, LA Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988;72:853-857.
21. Samadi AR, Lee NC, Flanders WD, Boring JR III, Paris EB. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health 1996;86:858-862.
22. Novak ER, Woodruff JD. Myoma and other benign tumors of the uterus. In: Novak's Gynecologic and Obstetric Pathology: with Clinical and Endocrine Relations, 8th ed. Philadelphia, PA: Saunders; 1979:260-279.
23. Palmoba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 2001;76:38-43.
24. de Visser J, Cert A, Feenstra H, van der Vies J. Endocrinological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Arzneimittelforschung 1984;34:1010-1017.
25. de Aloysio D, Altieri P, Penacchioni P, Salgarello M, Ventura V. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas 1998;29:261-264.
26. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
27. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
28. Erlik Y, Meldrum DR, Judd HL. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 1982;59:403-407.
29. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432-439.
30. Adams Hillard PJ. Menstruation in young girls: a clinical perspective. Obstet Gynecol 2002;99:655-662.
31. Schwartz SM, Marshall LM, Baird DD. Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ Health Prespect 2000;108(Suppl 5):821-827.
32. Matta WHM, Shaw RW, Nye M. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynaecol 1989;96:200-206.
33. Murphy AA, Morales AJ, Kettel LM, et al. Regression of uterine leiomyomata to the antiprogesterone RU486: dose response effect. Fertil Steril 1995;64:1870-1890.
34. Baird DD, Schectman JM, Dixon D, et al. African Americans at higher risk than whites for uterine fibroids: ultrasound evidence [Abstract]. Am J Epidemiol 1998;147:S90.